Collaborations & licenses
Our partnering strategy focuses on expanding and accelerating our ability to deliver transformational precision therapies to patients worldwide.
With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are committed to building a robust, industry-leading portfolio of precision therapies based on our proprietary drug discovery platform.
We actively seek collaboration or licensing opportunities that complement our existing portfolio and research focus. If you or your company are interested in partnering opportunities, please contact us.
In July 2020, we entered into a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize pralsetinib for the treatment of RET-altered cancers. Blueprint Medicines and Genentech are co-commercializing GAVRETO™ (pralsetinib) in the U.S., and Roche has exclusive commercialization rights for pralsetinib outside of the U.S., excluding Greater China. With Roche’s global reach and integrated personalized healthcare capabilities, this collaboration accelerates our ability to bring pralsetinib to patients around the world and expand development of pralsetinib across multiple treatment settings.
In March 2016, we entered into a global collaboration with Roche to discover, develop and commercialize small-molecule therapeutics targeting kinases believed to be important in cancer immunotherapy, either as monotherapies or combination therapies. The collaboration consists of four immunokinase targets, and Blueprint Medicines retains U.S. commercialization rights for up to two programs.
In June 2018, we entered into collaboration with CStone Pharmaceuticals to develop and commercialize our three lead clinical-stage therapeutic candidates avapritinib, fisogatinib and pralsetinib in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies. Blueprint Medicines retains all rights to avapritinib and fisogatinib in the rest of the world, and is collaborating with Roche to develop and commercialize pralsetinib
outside Greater China.
In October 2019, we entered into an exclusive, worldwide license agreement with Clementia Pharmaceuticals, a subsidiary of Ipsen, for BLU-782, an investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). Blueprint Medicines designed BLU-782 to selectively target mutant ALK2, the underlying cause of FOP, using our proprietary scientific platform. Ipsen’s global infrastructure and clinical expertise in FOP have the potential to accelerate clinical development of BLU-782 for FOP.